Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/febs.15521

http://scihub22266oqcxt.onion/10.1111/febs.15521
suck pdf from google scholar
32790936!7436654!32790936
unlimited free pdf from europmc32790936    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32790936      FEBS+J 2020 ; 287 (17): 3656-3663
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Nicotine and the nicotinic cholinergic system in COVID-19 #MMPMID32790936
  • Tizabi Y; Getachew B; Copeland RL; Aschner M
  • FEBS J 2020[Sep]; 287 (17): 3656-3663 PMID32790936show ga
  • There is an urgent need to address the devastating pandemic, COVID-19, caused by SARS-CoV-2. The efforts to understand the details of this disease in hope of providing effective treatments are commendable. It is clear now that the virus can cause far more damage in patients with comorbid conditions-particularly in those with respiratory, cardiovascular, or immune-compromised system-than in patients without such comorbidities. Drug use can further exacerbate the condition. In this regard, the ill effects of smoking are amply documented, and no doubt can be a confounding factor in COVID-19 progression. Although conflicting hypotheses on the potential role of nicotine in COVID-19 pathology have recently been offered, we believe that nicotine itself, through its interaction with the nicotinic cholinergic system, as well as ACE2, may not only be of use in a variety of neuropsychiatric and neurodegenerative diseases, but may also be of potential use in COVID-19. Thus, on one hand, while we strongly support smoking cessation as a means of harm reduction associated with COVID-19, on the other hand, we support a potential therapeutic role for nicotine, nicotinic agonists, or positive allosteric modulators of nicotinic cholinergic receptors in COVID-19, owing to their varied effects including mood regulation, anti-inflammatory, and purported interference with SARS-CoV-2 entry and/or replication.
  • |Angiotensin-Converting Enzyme 2/*genetics/immunology[MESH]
  • |COVID-19/genetics/immunology/*metabolism/virology[MESH]
  • |Cytokine Release Syndrome/genetics/immunology/*metabolism/virology[MESH]
  • |Gene Expression Regulation[MESH]
  • |Host-Pathogen Interactions/drug effects/genetics[MESH]
  • |Humans[MESH]
  • |Lung/drug effects/metabolism/pathology/virology[MESH]
  • |Nicotine/*pharmacology[MESH]
  • |Receptors, Nicotinic/*genetics/immunology[MESH]
  • |Receptors, Virus/genetics/immunology[MESH]
  • |SARS-CoV-2/immunology/pathogenicity[MESH]
  • |Severity of Illness Index[MESH]
  • |Signal Transduction[MESH]
  • |Smoking/genetics/immunology/*metabolism[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box